Abstract
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to singleagent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Keywords: ARDS, ALI, inflammatory lung injury, lung injury therapy, anti-inflammatory therapy, surfactant therapy, INO therapy, antioxidants, pharmacotherapy
Current Medicinal Chemistry
Title: Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome
Volume: 15 Issue: 19
Author(s): Krishnan Raghavendran, Gloria S. Pryhuber, Patricia R. Chess, Bruce A. Davidson, Paul R. Knight and Robert H. Notter
Affiliation:
Keywords: ARDS, ALI, inflammatory lung injury, lung injury therapy, anti-inflammatory therapy, surfactant therapy, INO therapy, antioxidants, pharmacotherapy
Abstract: Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to singleagent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.
Export Options
About this article
Cite this article as:
Raghavendran Krishnan, Pryhuber S. Gloria, Chess R. Patricia, Davidson A. Bruce, Knight R. Paul and Notter H. Robert, Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome, Current Medicinal Chemistry 2008; 15 (19) . https://dx.doi.org/10.2174/092986708785132942
DOI https://dx.doi.org/10.2174/092986708785132942 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Treatment of Infectious Diseases and Drug Resistance (Executive Editor: Vassil St. Georgiev)]
Current Pharmaceutical Design Site-Selective Labeling Strategies for Screening by NMR
Combinatorial Chemistry & High Throughput Screening Human Cancer Cell Line Based Approach of 1,3,4-thiadiazole and its Fused Ring: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Current Drug Targets Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV
Mini-Reviews in Medicinal Chemistry Automation of Biomolecular NMR Screening
Current Topics in Medicinal Chemistry Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Annotating Viral Genomes - A Cannon is Needed to Kill Mosquitoes
Current Bioinformatics ACE2; an ACE up the Sleeve?
Current Enzyme Inhibition A SAR Study: Evaluation of Bromo Derivatives of 8-Substituted Quinolines as Novel Anticancer Agents
Letters in Drug Design & Discovery Inhibitors of c-jun-N-Terminal Kinase (JNK)
Mini-Reviews in Medicinal Chemistry Antiviral Drug Discovery and Development for Mayaro Fever – What do we have so far?
Mini-Reviews in Medicinal Chemistry Metallic Nanoparticles: A New Frontier in the Fight Against Leishmaniasis
Current Medicinal Chemistry Deep Learning in the Quest for Compound Nomination for Fighting COVID-19
Current Medicinal Chemistry Quantification of Vitamin D at Different Levels of Clinical Worsening of COVID-19
Current Drug Metabolism Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Self-Medication with Antibiotics in Europe: A Case for Action
Current Drug Safety Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design